![healthcare](https://www.finsmes.com/wp-content/uploads/2016/08/healthcare-440x293.jpg)
GluBio Therapeutics Closes $22M Series A+ Financing
GluBio Therapeutics, a San Diego, CA- and Shangai, China-based biotech company focused on developing novel targeted protein degradation (TPD) drugs, closed a $22m Series A+ financing.
GluBio Therapeutics, a San Diego, CA- and Shangai, China-based biotech company focused on developing novel targeted protein degradation (TPD) drugs, closed a $22m Series A+ financing.
OriCell Therapeutics (Shanghai) Co., Ltd. , a Shangai, China-based developer of novel immunotherapies to satisfy globally unmet clinical needs, closed a Series B financing totaling over US$120m.
Chinese venture capital firm BAI Capital closed BAI Capital Fund I, L.P. and its related investment vehicles, with approximately US$700 million of total capital raised.
Boston Micro Fabrication (BMF), a Chongqing, China-based provider of microscale 3D printing systems, raised $43M in Series C funding.
Apache DolphinScheduler, a Beijing, China-based provider of a cloud native DataOps platform, raised nearly $10M in Angel financing.
Jaka Robotics, a Shangai, China-based collaborative robot company, raised approx. $150M in Series D funding.
Frontera Therapeutics, a Bedford, MA and Suzhou, China-based clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of patients across multiple disease areas, closed a $160m Series B funding round.
Xpeng Robotics, a Shenzen, China-based affiliate of XPeng Inc. and a key part of its mobility ecosystem dedicated to creating smart robots, raised over US$100 million in Series A funding.
Headline, a tech-enabled global venture capital firm, raised $954M in new capital across three distinct early-stage funds.
Jiangsu Huili Biotechnology Co., Ltd. (Huili Bio), a Hong Kong-based next-generation synthetic biology enzyme computational design platform, completed its Series A financing round with hundreds of million RMB.
Zhiyi Biotech, a Guangzhou, China-based biotechnology company, raised $45M in Series B funding.
ClinChoice, a Philadelphia, PA- and Shangai, China-based clinical CRO company, raised $150M in Series E funding.
Wissen Technology, a Beijing, China-based robot service innovator, raised US$10M in Pre-A+ Series funding.
Mojia Biotech, a Shanghai, China-based bio-manufacturing company, raised $80M in Series B funding.
MegaRobo Technologies, a Beijing, China-based provider of automation solutions, raised $300M in Series C funding.